Dr Reddy's launches toripalimab in India

Indian drugmaker Dr Reddy’s Laboratories (BSE: 500124) has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted.

It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).

In 2023, Dr Reddy’s entered into a license and commercialization agreement with Shanghai Junshi Biosciences (SSE: 688180) for toripalimab, which the Shanghai-based company markets as Loqtorzi. Under this accord, Dr Reddy’s obtained exclusive rights to develop and commercialise toripalimab in 21 countries including India, South Africa, Brazil and various countries in Latin America. Additionally, the agreement allows Dr Reddy’s to expand the scope of the license to cover Australia, New Zealand and nine other countries.